Logos Global Management as of March 31, 2021
Portfolio Holdings for Logos Global Management
Logos Global Management holds 53 positions in its portfolio as reported in the March 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Alx Oncology Hldgs (ALXO) | 22.7 | $233M | 3.2M | 73.74 | |
| Olema Pharmaceuticals (OLMA) | 12.1 | $124M | 3.7M | 33.18 | |
| Design Therapeutics (DSGN) | 8.0 | $82M | 2.7M | 29.90 | |
| Dyne Therapeutics (DYN) | 4.9 | $50M | 3.2M | 15.53 | |
| Instil Bio | 4.5 | $46M | 1.8M | 25.08 | |
| Nkarta (NKTX) | 4.0 | $42M | 1.3M | 32.90 | |
| Forma Therapeutics Hldgs SHS | 3.9 | $40M | 1.4M | 28.02 | |
| Edgewise Therapeutics (EWTX) | 3.4 | $34M | 1.1M | 32.50 | |
| Kinnate Biopharma (KNTE) | 2.8 | $29M | 935k | 31.16 | |
| Repare Therapeutics Ord (RPTX) | 2.7 | $28M | 900k | 30.69 | |
| Karuna Therapeutics Ord | 2.3 | $24M | 200k | 120.23 | |
| Bicycle Therapeutics Sponsored Ads (BCYC) | 2.3 | $24M | 800k | 29.87 | |
| Athira Pharma (ATHA) | 1.8 | $19M | 1.0M | 18.40 | |
| Bioxcel Therapeutics (BTAI) | 1.7 | $17M | 400k | 43.16 | |
| Cullinan Oncology (CGEM) | 1.7 | $17M | 414k | 41.67 | |
| Cytokinetics Com New (CYTK) | 1.6 | $16M | 700k | 23.26 | |
| Turning Point Therapeutics I | 1.3 | $13M | 140k | 94.59 | |
| Cogent Biosciences (COGT) | 1.2 | $13M | 1.4M | 8.78 | |
| Ikena Oncology (IKNA) | 1.2 | $12M | 420k | 28.25 | |
| Aligos Therapeutics (ALGS) | 1.1 | $11M | 477k | 22.74 | |
| Kymera Therapeutics (KYMR) | 1.0 | $10M | 261k | 38.86 | |
| Vincerx Pharma Com New (VINC) | 0.9 | $9.3M | 480k | 19.30 | |
| Compass Pathways Sponsored Ads (CMPS) | 0.9 | $9.2M | 250k | 36.82 | |
| Miragen Therapeutics (VRDN) | 0.9 | $9.2M | 550k | 16.71 | |
| Aslan Pharmaceuticals Ads | 0.8 | $7.7M | 2.3M | 3.35 | |
| Iveric Bio | 0.7 | $7.4M | 1.2M | 6.18 | |
| Kiniksa Pharmaceuticals Com Cl A (KNSA) | 0.7 | $7.4M | 400k | 18.51 | |
| Landos Biopharma | 0.7 | $7.1M | 734k | 9.63 | |
| Pmv Pharmaceuticals (PMVP) | 0.6 | $6.6M | 200k | 32.89 | |
| Harpoon Therapeutics | 0.6 | $6.3M | 300k | 20.92 | |
| Silverback Therapeutics (SPRY) | 0.5 | $5.5M | 125k | 43.63 | |
| Therapeutics Acquisition Cor Com Cl A | 0.5 | $5.3M | 500k | 10.51 | |
| Bolt Biotherapeutics (BOLT) | 0.5 | $4.9M | 150k | 32.91 | |
| Kezar Life Sciences (KZR) | 0.5 | $4.8M | 800k | 5.96 | |
| Annexon (ANNX) | 0.4 | $4.4M | 160k | 27.84 | |
| Viracta Therapeutics (VIRX) | 0.4 | $4.3M | 470k | 9.25 | |
| C4 Therapeutics Com Stk (CCCC) | 0.4 | $4.2M | 113k | 36.99 | |
| Larimar Therapeutics (LRMR) | 0.3 | $3.4M | 230k | 14.61 | |
| Health Sciences Acq Corp 2 Ord Shs | 0.3 | $3.4M | 300k | 11.19 | |
| Harmony Biosciences Hldgs In (HRMY) | 0.3 | $3.3M | 100k | 33.04 | |
| Research Alliance Corp Ii Com Cl A | 0.3 | $3.1M | 300k | 10.25 | |
| Lucira Health | 0.3 | $3.0M | 250k | 12.10 | |
| Fs Development Corp Ii Com Cl A | 0.3 | $3.0M | 300k | 9.96 | |
| Deciphera Pharmaceuticals (DCPH) | 0.3 | $2.8M | 62k | 44.84 | |
| Connect Biopharma Hldgs Ads (CNTB) | 0.3 | $2.8M | 150k | 18.50 | |
| Eargo | 0.2 | $2.5M | 50k | 49.96 | |
| Eledon Pharmaceuticals (ELDN) | 0.2 | $2.4M | 224k | 10.70 | |
| Bctg Acquisition Corp | 0.2 | $2.2M | 200k | 11.12 | |
| Passage Bio (PASG) | 0.2 | $2.2M | 125k | 17.48 | |
| Arya Sciences Acqu Corp Iv Cl A (ARYD) | 0.2 | $2.1M | 200k | 10.47 | |
| Helix Acquisition Corp Com Cl A | 0.2 | $2.0M | 200k | 10.20 | |
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $178k | 67k | 2.67 | |
| Cerevel Therapeutics Hldng I *w Exp 06/09/202 (CEREW) | 0.0 | $144k | 33k | 4.32 |
